# Mayo Clinic Hepatobiliary SPORE Diversity Supplement Dr. Musa Gabere

> **NIH NIH P50** · MAYO CLINIC ROCHESTER · 2021 · $136,012

## Abstract

STATEMENT OF CANDIDATE ELIGIBILITY AND DIVERSITY
Dr. Musa Gabere is a permanent resident of the United States (Green card number: 063-359-769) of African
descent. He completed his undergraduate studies at the University of Nairobi. He then moved to South Africa,
where he completed post-graduate diploma, Master of Science and Doctor of Philosophy.
Dr. Gabere is interested in applying genetics and bioinformatics approaches to identify common biomarkers
that can be used to develop targeted therapies for hepatobiliary cancers. In particular, he will train in
understanding the transcriptome changes in hepatocarcinoma treated with immunovirotherapy, a new class of
immunotherapeutic. He will be mentored by Dr. Mitesh J. Borad (Primary mentor), Dr. Richard G. Vile (Co-
mentor), and Dr. Lewis Roberts (co-mentor) as part of the parent grant 5P50CA210964-03 (P.I. Dr. Richard G.
Vile).
The overall goal of Dr. Gabere is to pursue research in cancer genetics. Dr. Gabere will participate in various
training in Mayo Clinic. These include training in virotherapy, immunotherapy, translational research and ethics.
Additionally, there are weekly meetings in cancer, where he can learn and interact with Mayo Clinic Cancer
Center senior investigators. In addition, to this, Dr Gabere will have the opportunity to work with large cancer
genetics datasets with experts in liver and pancreatic cancer research. These datasets include but not
restricted to whole genome, exome, methylome, metabolome and transcriptome for various cancers such as
Cholangiocarcinoma. Dr Gabere will also have opportunity to mentor and supervise PhD students and visiting
scientists to identify of antigens both in-silico and functional assays.
The diversity grant will also allow Dr. Gabere to increase the number of racial and ethnic minorities who
participate in biomarker discovery and clinical trials. This will allow Dr Gabere to inform and educate the
minorities in the importance of clinical trials and early cancer screening. It is expected that upon receipt of the
Diversity Supplement, Dr. Gabere will be able to generate vital data and apply for extramural funding, such as
the care award (R21) at the end of his second year.

## Key facts

- **NIH application ID:** 10310895
- **Project number:** 3P50CA210964-04S2
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **Principal Investigator:** MARK A. MC NIVEN
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $136,012
- **Award type:** 3
- **Project period:** 2018-09-10 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10310895

## Citation

> US National Institutes of Health, RePORTER application 10310895, Mayo Clinic Hepatobiliary SPORE Diversity Supplement Dr. Musa Gabere (3P50CA210964-04S2). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10310895. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*